(8-10 minutes) Antibody selection is one of the most influential decisions made during early Lateral Flow Assay (LFA) development. Whether antibodies are sourced commercially or developed as part of a broader LFA development service, the choices made at this stage directly affect assay sensitivity, specificity, reproducibility and long-term manufacturability. Applying a structured, risk based approach to antibody evaluation can significantly reduce technical and commercial ch
